Gain Therapeutics, Inc. 8-K

What Happened Gain Therapeutics, Inc. (GANX) filed an 8-K on June 25, 2026 reporting the results of its annual meeting of stockholders. A quorum was present and the stockholders elected seven directors—Gene Mack, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D., Gwen Melincoff, Claude Nicaise, M.D., and Jeffrey Riley—to one‑year terms. The meeting also ratified the appointment of Ernst & Young AG as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Meeting date / filing: Annual meeting reported in 8‑K filed June 25, 2026; quorum present.
• Directors elected (votes For / Withheld / Broker Non‑Vote):
  • Gene Mack: 13,618,503 For / 1,691,620 Withheld / 11,670,126 Broker Non‑Vote
  • Dov Goldstein, M.D.: 14,477,046 For / 833,077 Withheld / 11,670,126 Broker Non‑Vote
  • Hans Peter Hasler: 13,517,744 For / 1,792,379 Withheld / 11,670,126 Broker Non‑Vote
  • Khalid Islam, Ph.D.: 14,393,372 For / 916,751 Withheld / 11,670,126 Broker Non‑Vote
  • Gwen Melincoff: 14,459,942 For / 850,181 Withheld / 11,670,126 Broker Non‑Vote
  • Claude Nicaise, M.D.: 14,472,350 For / 837,773 Withheld / 11,670,126 Broker Non‑Vote
  • Jeffrey Riley: 14,148,296 For / 1,161,827 Withheld / 11,670,126 Broker Non‑Vote
• Auditor ratification vote: Ernst & Young AG approved with 25,865,468 For, 1,074,319 Against, and 40,462 Abstain.

Why It Matters The filing confirms the company’s board composition for the coming year and formalizes Ernst & Young AG as Gain Therapeutics’ auditor for fiscal 2026. For investors, these are governance outcomes—showing management and shareholder support for the current board slate and continuity of the external audit relationship, both relevant to oversight and financial reporting reliability.